AllerGen NCE Inc. is governed by an independent Board of Directors (BoD) committed to the vision and mission of the Network. Board Directors promote an atmosphere where research excellence and industry expertise unite to provide socio-economic benefits for Canadians. The BoD is responsible for the overall governance of the Network and acts in accordance with the By-Laws of AllerGen NCE Inc.
AllerGen’s BoD ensures that Network management pursues appropriate corporate directions and develops, maintains and implements investments, processes and strategic plans in accordance with Network policies and priorities.
Current Board Members
Pieter Cullis (Chair) | academic/research, Vancouver BC
Pieter Cullis, PhD, FRSC (Chair)
Director, Life Sciences Institute; Director, NanoMedicines Research Group; Chair, Personalized Medicine Initiative; Professor, Department of Biochemistry and Molecular Biology, The University of British Columbia
Dr. Cullis is an internationally recognized pioneer and leader in the physical properties and functional roles of lipids in biological membranes and liposomal drug delivery systems.
Donald Green (Vice Chair) | industry, Burlington ON
Chair and CEO, Greenfleet Ltd.
For 35 years, Donald Green was Chair and CEO of the international auto parts manufacturer Tridon Ltd., and is now Chair and CEO of Greenfleet Ltd., a private investment company.
Patrick Deane | academic, Hamilton ON
President and Vice-Chancellor, McMaster University
Dr. Deane is the seventh and current president and vice-chancellor of McMaster University.
Sector: Academic (Host Institution)
Judah Denburg | clinical/academic, Hamilton ON
Scientific Director and CEO, AllerGen NCE Inc.
As Scientific Director of AllerGen, Dr. Denburg helps steer an innovative and inter-disciplinary research program. Dr. Denburg’s main research thrusts include examination of the mechanisms of allergic inflammation, with particular emphasis on hemopoietic cytokines and their role in activating the differentiation and recruitment of inflammatory cells such as eosinophils, basophils and mast cells.
Vanessa Foran | non-profit, Toronto ON
Charles Frankish | clinical, Kanata ON
Treasurer, Canadian Allergy, Asthma and Immunology Foundation (CAAIF); Allergist and Clinical Immunologist, Kanata Allergy Services
Dr. Frankish is an allergist and clinical immunologist at Kanata Allergy Services in Kanata, ON.
Christine Hampson | non-profit, Toronto ON
President and CEO, The Sandbox Project
Dr. Hampson is President & CEO of The Sandbox Project Charity, which aims to make measurable progress against international health indicators within the next five years, improving health outcomes with respect to injury prevention, obesity, mental health, and the environment in particular.
Jean-François LePrince | private, Montreal QC
Managing Partner, CTI Life Sciences Fund
Mr. Leprince has over 30 years of experience with large pharmaceutical companies; he has overseen the largest R&D spending of any of the multinational pharmaceutical companies operating in Canada.
Daniel Nixon | private, Toronto ON
Director & Chief Financial Officer, Molecular You Corporation
Mr. Nixon is a seasoned executive with extensive private equity, investment banking and operations experience.
Paul O'Byrne | clinical/academic, Hamilton ON
Professor, Division of Respirology, Department of Medicine, and Dean and Vice-President, Faculty of Health Sciences, McMaster University, St. Joseph’s Healthcare
Dr. O’Byrne is world renowned for his research on asthma that is the result of allergies.
Donald Stark | clinical/academic, Vancouver BC
Clinical Associate Professor, Department of Medicine, The University of British Columbia
Dr. Stark was president of the Canadian Society of Allergy and Clinical Immunology from 1990 to 1992 and was instrumental in setting up the Canadian Allergy, Asthma and Immunology Foundation, serving as its first Chairman.
Teresa To | academic, Toronto, ON
Professor, Dalla Lana Graduate School of Public Health, University of Toronto; Senior Scientist, Child Health Evaluative Sciences, Research Institute, Hospital for Sick Children
Dr. Teresa To’s population-based research program focuses on childhood asthma. Using paediatric health databases, she examines factors that influence the health of children with asthma and their health outcomes. Her current asthma care research program spans acute, primary care settings to population levels.
Lorne Tyrrell | clinical/academic, Edmonton, AB
Distinguished University Professor and Director, LiKaShing Institute of Virology, University of Alberta
Dr. Tyrrell, an exceptional teacher, compassionate physician and accomplished researcher, has positioned the University of Alberta and Canada as a world leader in hepatitis research and treatment. He was awarded a Killam Prize in 2015.
Laura Feldman (observer) | AllerGen NCE
Laura received her B.Sc. in Environment and Health from The University of Toronto in 2014, and her Masters of Public Health degree from The Dalla Lana School of Public Health, University of Toronto, in 2016. Laura is presently working with Dr. Teresa To at the Hospital for Sick Children.
Pascal Marchand (observer) | NCE Secretariat
Diana Royce (observer) | AllerGen NCE
Diana Royce, EdD (observer)
Managing Director and COO, AllerGen NCE Inc.
Dr. Royce has over 30 years of experience in the post-secondary and health sectors related to public consultation and research, program implementation, strategic and operational planning, network administration, partnership and public policy development, advocacy, fundraising, knowledge mobilization, conference planning and meeting facilitation.